Name: Azetukalner (XEN1101) in Focal onset seizures: Economic impact of diagnostic testing
Published: 2026-09-21T21:41:53-04:00

Product information and disease description Place of product in therapy Disease description Burden of Focal onset seizures

Economic impact of diagnostic testing

3 evidence topics · 3 sources

Comparative cost of ambulatory electroencephalography and inpatient video-electroencephalography monitoring

“In a large retrospective cohort study of 13,958 patients, outpatient AEEG cost was significantly lower compared to inpatient VEM monitoring.” (opens the source at this quote in a new tab)
“These findings were similar to original economic models which indicated that AEEG was up to 66% cheaper than inpatient VEM” (opens the source at this quote in a new tab)
“Since January 1, 2020, in the United States, reimbursement for long-term inpatient EEG monitoring modified the fee structure for VEM and AEEG reimbursement for professional and technical components” (opens the source at this quote in a new tab)

Health care utilization before and after seizure monitoring unit admission, Canadian cohort

“A total of 315 of 600 (53%) patients met eligibility criteria. Mean age was 40 years (SD = 17.4), 176 (56%) were female, 220 (70%) had focal epilepsy, and 60 (19%) had functional seizures or physiologic seizure mimics without epilepsy as adjudicated by the attending physician at the point of discharge.” (opens the source at this quote in a new tab)
“Admission to an SMU is associated with significant and enduring declines in HCU.” (opens the source at this quote in a new tab)

Diagnostic uncertainty as a cost driver

“These findings highlight the impact of diagnostic uncertainty and care fragmentation, suggesting that improved identification and healthcare coordination could enhance outcomes and reduce inefficiencies.” (opens the source at this quote in a new tab)